Food and Drug Administration: Compounding and the FDA: Questions and Answers Johns Hopkins Medicine: Maintaining Weight Loss Kom AM et al
However, the net benefit of the drug in terms of cardiovascular health and mortality is still to be determined in longer-term follow-up trials
Semaglutide treatment is suitable for adults with a BMI of 30 or higher (indicating obesity) or a BMI of 27 or higher (considered overweight) with obesity-related health conditions
These medications can be associated with significant ocular complications, according to a new clinical report by the AOAs Evidence-based Optometry Committee
This slow escalation allows your body to adapt to the appetite suppression and gastrointestinal changes caused by semaglutide, reducing the risk of severe nausea, vomiting, or other side effects that might force you to discontinue treatment early
If they are unsuccessful, or find it hard to lose weight, you can offer them anti-obesity medications